Alzheimer's disease (AD) is characterized by deficits in cerebral metabolic rates of glucose in the posterior cingulate (PC) and precuneus in AD subjects, and in APOEε4 carriers, decades before the onset of measureable cognitive deficits. However, the cellular and molecular basis of this phenotype remains to be clarified. Given the roles of astrocytes in energy storage and brain immunity, we sought to characterize the transcriptome of AD PC astrocytes. Cells were laser capture microdissected from AD (n ¼ 10) and healthy elderly control (n ¼ 10) subjects for RNA sequencing. We generated >5.22 billion reads and compared sequencing data between controls and AD patients. We identified differentially expressed mitochondria-related genes including TRMT61B, FASTKD2, and NDUFA4L2, and using pathway and weighted gene coexpression analyses, we identified differentially expressed immune response genes. A number of these genes, including CLU, C3, and CD74, have been implicated in beta amyloid generation or clearance. These data provide key insights into astrocyte-specific contributions to AD, and we present this data set as a publicly available resource.
Introduction
With the rapidly growing prevalence of Alzheimer's disease (AD), improved understanding of the molecular and cellular basis of the disease is needed to identify and develop improved diagnostics and treatments. Numerous imaging studies have set the stage for characterizing AD in live subjects. Using fluorodeoxyglucose position emission tomography (FDG-PET), researchers have characterized an association between AD and progressive reductions of cerebral metabolic rates of glucose (CMRgI) in both AD patients (Minoshima et al., 1997; Reiman et al., 1996 Reiman et al., , 2001 Reiman et al., , 2004 and young adult APOEε4 carriers 4 decades before the expected onset of cognitive deficits (Reiman et al., 2004) . Affected brain regions include the posterior cingulate (PC) and parietal, temporal, and frontal cortices (Alexander et al., 2002; Fox et al., 2000; Minoshima et al., 1997; Thal et al., 2006) , with the PC and precuneus demonstrating the earliest metabolic deficits in AD (Minoshima et al., 1997; Reiman et al., 2004) . Such deficits may be associated with metabolic dysfunctions in neurons or glial cells (Mark et al., 1997; Piert et al., 1996) , reductions in the density or activity of terminal neuronal fields or perisynaptic glial cells (Magistretti and Pellerin, 1996; Schwartz et al., 1979) , or a combination of both, and additionally highlights a metabolic role of the PC in AD.
In previous work, we identified widespread downregulated expression of electron transport and mitochondrial translocase genes in non-tangle bearing neurons microdissected from the PC of AD subjects (Liang et al., 2008a (Liang et al., , 2008b . In a separate study, decreased cytochrome c oxidase activity was also identified across all 6 layers of the PC cortex in AD subjects (Valla et al., 2001) . Although these findings provide evidence that mitochondrial dysfunction may play a role in characteristic CMRgI deficits in AD, it is unclear as to what pathogenic contributions may be derived from astrocytes in the PC. Importantly, previous studies have shown that astrocytes demonstrate changes with respect to aging and AD. Examples include the occurrence of structural changes in astrocytes in the dentate gyrus of aged rats (Geinisman et al., 1978) , distinct clustering of astrocytes and astroglial hypertrophy in the hippocampi of aged rats (Landfield et al., 1977) , release of proinflammatory factors from astrocytes in AD (Akiyama et al., 2000) , and buildup of beta amyloid (Ab) molecules within astrocytes (Akiyama et al., 2000) , which may result from deficits in the ability of the cell to degrade Ab, and recent work suggesting that activation of glial cells may have a primary role in impacting the health of neurons in AD (Perez-Nievas et al., 2013) . Given this previous research and astrocytes' roles in energy storage and metabolism (Pellerin and Magistretti, 1994; Tsacopoulos and Magistretti, 1996) , immunity (Jensen et al., 2013) , and the greater than 2-fold increase in the number of astrocytes compared with neurons in the human brain (Jensen et al., 2013; Nedergaard et al., 2003; Sherwood et al., 2006; Sofroniew and Vinters, 2010) , we hypothesized that PC astrocytes demonstrate significant expression changes in AD. With the role of astrocytes in energy storage and metabolism, we further hypothesize that genes involved in mitochondrial processes are also dysregulated in AD PC astrocytes.
A number of studies have evaluated human and murine astrocyte transcriptomes using microarray technology (Cahoy et al., 2008; Hawrylycz et al., 2012; Simpson et al., 2011; Yasui et al., 2013) or focused approaches such as Northern blotting (Pasternack et al., 1989) or real time polymerase chain reaction (PCR) (Zhao et al., 2011) . Simpson et al. (2011) expression profiled glial fibrillary acidic protein (GFAP) positive astrocytes microdissected from the temporal cortex of elderly subjects and identified differentially expressed genes with respect to Braak stage and apolipoprotein (APOE) ε4 carrier status. In a separate study, cortical astrocytes were collected from young and old mice and expression profiled to reveal altered expression of key genes involved in neuronal signaling (Orre et al., 2014) . In this study, we used laser capture microdissection (LCM) to collect aldehyde dehydrogenase 1 family, member L1-(ALDH1L1) positive astrocytes from PC cortex in both AD subjects (n ¼ 10) and healthy elderly controls (n ¼ 10). GFAP was not used in our study because of a number of caveats with this marker including: (Minoshima et al., 1997) GFAP demonstrates varying levels of expression across different cell types and regions (Roelofs et al., 2005; Sofroniew, 2009; Sofroniew and Vinters, 2010) , is expressed in other glial cells outside of astrocytes (Sofroniew and Vinters, 2010) , is highly expressed in reactive astrocytes (Eng et al., 2000; Pekny and Pekna, 2004; Pekny et al., 1995; Sofroniew and Vinters, 2010) , and is often not identifiable in healthy tissue (Sofroniew and Vinters, 2010) . However, ALDH1L1 is more specific to astrocytes than GFAP, does not preferentially mark reactive astrocytes, is expressed in mature astrocytes, and demonstrates a wider pattern of expression compared with GFAP such that GFAP-positive cells make up a subset of ALDH1L1-positive cells (Eng et al., 2000; Pekny and Pekna, 2004; Pekny et al., 1995; Sofroniew and Vinters, 2010) . It is also important to note that our previous analysis of PC neurons was limited by the use of microarrays that used predefined probes to target only nuclear-encoded, and not mitochondrially-encoded, genes. However, in our study here, we capitalize on current genomic technologies to perform an unbiased evaluation of all transcripts present in each sample and to take advantage of the increased analytical sensitivity and wide dynamic range associated with next generation sequencing. We thus performed next generation RNA sequencing (RNAseq) of astrocyte total RNA and describe here the first reported sequencing data set of PC astrocytes in AD.
Methods

Sample acquisition
Postmortem brain samples were collected at the Banner Sun Health Research Institute's Brain and Body Donation Program from 10 clinically classified late-onset AD subjects (4 males and 6 females; 5 APOEε3/4 subjects and 5 APOEε4/4 subjects) with a mean age at death of 83.9 years and 10 no disease (ND) healthy elderly control subjects (6 males and 4 females; 5 APOEε3/4 subjects and 5 APOEε4/4 subjects) with a mean age of death of 85.1 years. Clinically confirmed AD subjects had Braak stages ranging from IV to VI (Braak and Braak, 1991) and neuritic plaque densities of frequent (McKhann et al., 1984) . Control subjects had Braak stages ranging from I to IV, plaque densities ranging from zero to moderate, and were clinically confirmed to not demonstrate dementia. Samples were collected with a mean postmortem interval (PMI) of 2.42 hours from the PC cortex (Brodmann areas 23 and 31). Following dissection, samples were flash frozen, sectioned (10 mm), and mounted on glass or PEN membrane slides (Carl Zeiss Microscopy; Thornwood, NY). Information for each subject is shown in Table 1 . Total RNA was isolated from a single section from each subject using the Qiagen RNeasy kit to evaluate RNA integrity. Samples demonstrated Agilent Bioanalyzer RNA Integrity Number (RINs) between 7.4 and 9.4 such that all samples were used for downstream analyses.
Staining and laser capture microdissection
PC brain sections were rapidly stained with Alexa Fluor 350 conjugated ALDH1L1 (anti-Aldehyde Dehydrogenase 1 Family, Member L1) rabbit polyclonal antibody (ABIN882166; antibodiesonline; Atlanta, GA) to identify astrocytes. For each section, antibody was diluted 1:100 in phosphate-buffered saline (PBS) with ProtectRNA RNase inhibitor (Sigma-Aldrich; St. Louis, MO). For staining, each section was first fixed in ice-cold acetone for 3 minutes, washed 3X with PBS with RNase inhibitor, and diluted ALDH1L1 antibody was applied and incubated in the dark on ice for 10 minutes. The section was then washed 3X with PBS with RNase inhibitor, followed by consecutive washes with molecular water, 70% ethanol, 95% ethanol, and 100% ethanol. The section was then allowed to dry at room temperature. For each subject, approximately 300 astrocytes were LCMed from PC cortex onto the caps of AdhesiveCap opaque tubes (Carl Zeiss Microscopy) using the PALM LCM System (Carl Zeiss Microscopy; Thornwood, NY). Examples of ALDH1L1þ astrocytes, as well as a pre-and postLCMed astrocyte, are shown in Supplementary Fig 1. Extraction buffer (10 mL) from the Arcturus PicoPure RNA Isolation Kit (Life Technologies; Grand Island, NY) was pipetted directly onto the cap and incubated at 42 C for 30 minutes to create cell lysate. Lysates were collected by centrifugation at 800xg for 2 minutes and stored at À80 C until all samples were microdissected.
RNA isolation
Total RNA was isolated from all cell lysates using the Arcturus PicoPure RNA Isolation Kit (Life Technologies; Grand Island, NY) following the manufacturer's protocol. DNase treatment was additionally performed during RNA isolation using the RNase-free DNase set (Qiagen; Valencia, CA) following Appendix A of the Arcturus PicoPure manufacturer's protocol.
Library preparation
All isolated total RNA from each LCM collection was used to generate and linearly amplify cDNA using the Ovation RNAseq System v2 (Nugen; San Carlos, CA) following the manufacturer's protocol. This system uses a primer mix to initiate amplification from the 3 0 end of genes as well as throughout the entire transcriptome. Amplified cDNA was input into the TruSeq DNA Sample Preparation Kit v2 (Illumina; San Diego, CA) and sequencing libraries were generated following the manufacturer's protocol with the exception that 10 cycles of PCR was used for library enrichment. Final libraries were analyzed on a Bioanalyzer DNA 1000 chip (Agilent Technologies; Santa Clara, CA). Equimolar pools of libraries were created for sequencing and reassessed on the Bioanalyzer before sequencing.
Paired-end sequencing
Library pools were clustered onto Illumina v3 flowcells using the Illumina Truseq PE Cluster Kit v3 on the Illumina cBot. Clustered flowcells were sequenced by synthesis on the Illumina HiSeq2000 using Illumina's Truseq PE Cluster Kit v3 and Illumina's TruSeq SBS Kits v3 for paired 83 base pair read lengths.
Sequencing data analysis
Raw sequencing data in the form of BCL files were converted to FASTQ files using Illumina BCLConverter software. Data were aligned against the human reference genome (build 37) using TopHat1.2 (Trapnell et al., 2009 (Trapnell et al., , 2012 and Cufflinks (Trapnell et al., 2012 ) was used to assemble aligned reads into transcripts. HTSeq (http:// www-huber.embl.de/users/anders/HTSeq/doc/overview.html) was used to generate a counts table from Cufflinks output and DESeq2 v1.4.0 (Anders and Huber, 2010) (http://www.bioconductor.org/ packages/devel/bioc/html/DESeq2.html) was used to calculate normalized read counts for each gene and/or transcript and to perform expression analysis. To evaluate inter-sample variability, we performed Pearson correlation analyses in R using normalized counts across all samples to identify any outliers.
DESeq2 uses a generalized linear model to evaluate differential expression while accounting for biological variance and uses a Wald test statistic to evaluate significance. A DESeqDataSet object is created using HTSeq counts and the DESeq wrapper function is called to perform differential analyses. The fold change is determined by dividing the average normalized read counts of AD samples over control samples for each transcript. Independent filtering and Cook cutoff parameters were set to ON to remove outliers and genes with low normalized read counts. p-values were corrected using the Benjamini and Hochberg False Discovery Rate, and results were annotated using the Biomart online portal (http:// www.ensembl.org/biomart/martview).
MetaCore from Thompson Reuters (v6.10 build 40,284) was used for GeneGo pathway analysis. Weighted gene co-expression network analysis (WGCNA) (Horvath et al., 2006; Zhang and Horvath, 2005) was performed on differentially expressed genes (corrected p < 0.05). Gene sets were loaded into the WGCNA R package, and annotation of generated modules was performed using DAVID (Dennis et al., 2003) .
All data generated through this study are accessible through National Center for Biotechnology Information (NCBI) database of genotypes and phenotypes (dbGaP; accession phs000745.v1.p1).
Quantitative-polymerase chain reaction validation
Quantitative-polymerase chain reaction (qPCR) was performed to experimentally validate differentially expressed transcripts in 2 phases: first, qPCR was performed on total RNA from astrocytes microdissected from 3 control subjects and 3 AD subjects and second, across total RNA isolated from whole PC sections from all 20 sequenced subjects (during initial sample quality control analyses described in Section 2.1). For the first phase, validation was performed on cDNA synthesized and linearly amplified from LCMed astrocyte pools using the Nugen Ovation RNA-Seq System V2 kit. Additional remaining cDNA from original collections used for sequencing were used for validations for AD4, AD6, and ND9. Based on sample availability, newly microdissected astrocyte pools were collected for AD8, ND1, and ND2. Total RNA was isolated using the PicoPure RNA Isolation kit and was used to generate cDNA for validation using the Nugen Ovation RNA-Seq System V2 kit. determine binding efficiency of each primer. QPCR reactions were performed in 10 mL reactions using QuantiFast SYBR Green RT-PCR kit (Hilden, Germany) per the manufacturer's instructions on the Roche Lightcycler 480 system (Basel, Switzerland), with the exception that the initial reverse transcription step was omitted. Reactions were performed in triplicate with 1 nontemplate control.
Result and discussion
RNA sequencing
We sequenced 10 AD PC astrocyte pools and 10 ND (control) PC astrocyte pools to generate over 5.22 billion total reads and over 295 Gb of Q30 sequencing data. Both AD and ND groups were controlled for APOE genotype. An average of 123,214,013 mapped reads were sequenced per sample. Pearson correlation analyses on normalized read counts across all samples resulted in r values all greater than 0.88. All samples were thus included for differential expression analyses.
Differentially expressed genes in AD PC astrocytes
Comparison of AD samples with controls led to the identification of 226 differentially expressed genes (corrected p < 0.05; Supplementary Table 1) . Genes demonstrating the greatest log2-fold changes are shown in Fig. 1 . A total of 55.8% of significant genes demonstrated up regulated expression.
Differentially expressed genes include mitochondrial genes, defined as mitochondrially encoded genes or MitoCarta genes (Pagliarini et al., 2008) (Table 2 ). These genes include Fas-activated serine/threonine phosphoprotein kinase domains 2(FASTKD2; log2 ratio ¼ À3.50), tRNA methyltransferase 61 homolog B (TRMT61B; log2 ratio ¼ À2.81), pitrilysin metalloproteinase 1 antisense RNA 1 (PREP/MP1; PITRM1-AS1; log2 ratio ¼ À3.20), NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4-like 2(NDUFA4L2; log2 ratio ¼ 3.23), and mitochondrially encoded NADH dehydrogenase 1 pseudogene 22(MTND1P22; log2 ratio ¼ 6.71). FASTKD2, which localizes to the mitochondrial matrix, has been predicted to be involved in regulating apoptosis in breast cancer such that knockdown of the gene resulted in inhibition of apoptosis (Yeung et al., 2011) . Homozygous nonsense mutations in FASTKD2 have also been previously reported in mitochondrial encephalomyopathy, a condition associated with decreased cytochrome c oxidase activity (Ghezzi et al., 2008) . Decreased expression of FASTKD2 in AD PC astrocytes thus suggests perturbation of apoptosis regulation in these cells. TRMT61B, which also localizes to mitochondria, methylates adenosine at position 58 of cytoplasmic mitochondrial transport RNAs (tRNAs) and is hypothesized to improve processing, stability, or function of tRNAs required for translation of respiratory factors (Chujo and Suzuki, 2012) .
PITRM1/PREP/MP1 encodes an enzyme that is localized to the mitochondrial matrix (Chow et al., 2009) and that has been shown to degrade Ab (Falkevall et al., 2006) . Activity of this enzyme has also been reported to be decreased in the temporal lobe of AD subjects and transgenic AD murine brains (Alikhani et al., 2011) . Decreased expression of a transcript antisense to PITRM1 may be associated with changes in regulation of PITRM1 expression. NDUFA4L2 has been reported to inhibit activity of complex I under hypoxic conditions through hypoxia-inducible transcription factor-1 (HIF-1) (Tello et al., 2011) such that its increased expression in AD PC astrocytes may impact complex I activity. Finally, we identified altered expression of a mitochondrially encoded pseudogene, MTND1P22. Pseudogenes, represented by DNA sequences that are similar to protein-coding genes but do not generate functional proteins, have historically been assumed to be nonfunctional but more recent research suggests that pseudogene transcripts may represent regulatory long noncoding RNAs (Poliseno, 2012) . The differentially expressed mitochondrial pseudogene identified here is an unprocessed pseudogene, resulting from gene duplication, whereas processed pseudogenes result from a retrotransposition event (Poliseno, 2012) . To date, there have been no reports of biological evidence of mitochondrially encoded pseudogenes, although nuclear-encoded mitochondrial pseudogenes are known (Woischnik and Moraes, 2002) . Our understanding of these pseudogenes remains limited. However, given our current understanding of pseudogenes and the sequence similarity of this transcript with the NADH dehydrogenase 1 gene, MTND1P22 may have a role in transcription regulation. Additional differentially expressed mitochondrial genes include CTP synthase 2 (CTPS2; log2 ratio ¼ 3.15), mitochondrial ribosomal protein S2 (MRPS2; log2 ratio ¼ 2.88), methylenetetrahydrofolate dehydrogenase (NADPþ dependent) 2, methenyltetrahydrofolate cyclohydrolase (MTHFD2; log2 ratio ¼ À3.18), and transporter 1, ATP-binding cassette, subfamily B (TAP1; log2 ratio ¼ 2.83).
Pathway analysis of differentially expressed genes revealed that the most significantly impacted pathway in AD PC astrocytes is immune system response (Table 3 ) with 82.4% of significant genes in this pathway demonstrating upregulated expression in AD PC astrocytes. Furthermore, WGCNA, which performs functional organization of genes based on coexpression, on differentially expressed genes in AD astrocytes generated 7 coexpression modules, whereby the largest module ( Fig. 2A ; turquoise module) demonstrated the highest DAVID enrichment scores for immune response and immune processes, including antigen processing and presentation and lymphocyte activation. Genes in each module are shown in Fig. 2B . Given the role of astrocytes in central nervous system immunity under circumstances when insults are present (Jensen et al., 2013) , identification that immune system response processes are the most heavily perturbed pathways in AD PC astrocytes correlates with known astrocyte functions. These changes may be associated with activation of astrocytes in response to one or all the following: the presence of beta-amyloid, weakening of the blood-brain barrier (BBB), and exposure of sequenced cells to inflammatory cytokines. Differentially expressed immune system response genes include clusterin (CLU), apolipoprotein J (APOJ) (log2 ratio ¼ 1.97), complement component 3 (C3; log2 ratio ¼ 2.82), and cluster of differentiation 74 molecule, major histocompatibility complex, class II invariant chain (CD74; log2 ratio ¼ 3.52). Two large genome-wide association studies that evaluated over 23,000 individuals implicated an SNP, rs11136000, in CLU that is associated with late-onset AD (Harold et al., 2009; Lambert et al., 2009) . CLU encodes a heterodimeric chaperone that has been found to inhibit Ab oligomer uptake in human astrocytes (Mulder et al., 2014) such that increased expression of this gene in AD PC astrocytes may affect Ab clearance. C3 encodes a member of the complement system, and this gene has been reported to demonstrate an age-related increase in expression in control (C57BL/6) mice with more significant increases in transgenic amyloid precursor protein (APP) mice during formation of Ab (Reichwald et al., 2009 ). Finally, we identified upregulated expression of CD74 in AD PC astrocytes. CD74, which is involved in antigen presentation to T cells during an immune response, has also been found to interact with Ab and obstruct Ab production in HeLa cells (Matsuda et al., 2009) . Upregulated expression of CD74 in AD PC astrocytes may thus represent an effect resulting from multiple causes encompassing both immune system and Ab responses. Notably, the immune system response genes described here have all been shown to be associated with APP/Ab such that APP/Ab may be a key initiating factor in immune response pathways. Of relevance, the proximity of LCMed astrocytes to Ab plaques was not evaluated during microdissection, but the findings reported here may be influenced by the higher plaque load in the AD subjects.
Experimental validation of differentially expressed genes
Based on sample availability, qPCR experiments were performed to validate expression changes. qPCR was first performed across 3 control and 3 AD subjects using cDNA generated from total RNA isolated from microdissected PC astrocytes to validate gene expression changes of 7 selected differentially expressed genes, or transcripts, identified through the AD versus ND comparison (Supplementary Fig. 2A and B) . These genes and/or transcripts include RP11-488L18.10, RP11-797H7.1, TRMT61B, PPP5C, C3, TBP, and CLU. Because of limited availability of these samples, we also performed qPCR validation on total RNA that was isolated from an entire PC section from each subject during initial sample quality control analyses (n ¼ 20; Supplementary Fig. 2A and C) . These analyses were performed on 6 selected differentially expressed genes including TRMT61B, CTPS2, NDUF4AL2, CD74, CLU, and C3. Overall, the directionality of expression changes was validated across all genes. Notably, CLU and C3, both of which were evaluated by qPCR in microdissected astrocytes and whole PC sections, demonstrated larger increases in the astrocyte-specific data and lower increases in whole PC sections to show that the astrocytespecific signal is diluted in whole PC sections.
Conclusions
In this study, we identified altered expression of mitochondrial and immune system response genes in PC astrocytes in the context of AD. Based on WGCNA and pathway analyses, immune response processes appear to be most heavily impacted in PC astrocytes in AD subjects. These results provide evidence that brain immunity and mitochondrial functions in PC astrocytes are perturbed in AD.
Given the role of astrocytes as immune sensors in the brain (Jensen et al., 2013) , these cells may represent a first line of defense in response to insults, which may include inflammation, injury, or infection. Differentially expressed immune response genes in AD subjects include numerous genes that have been previously implicated as having key roles associated with Ab production and clearance. However, it remains to be clarified if alterations in immunity pathways parallel, overlap, or potentially precede, Ab formation. Deeper investigations into young pre-AD and MCI (mild cognitive impairment) subjects will be needed to determine if immune response processes are similarly affected before onset of AD, and if perturbation of immune response pathways coincides with CMRgI deficits seen in young APOEε4 carriers. Likewise, additional regional analyses are needed to evaluate if immune response pathways are also heavily impacted in brain regions differentially affected by AD. Although this study lends new insight into astrocytic changes in AD, we are limited by a few caveats. Although microdissection was used to collect astrocytes for sequencing, it is possible that fragments of adjacent endothelial cells or neurons may have also been collected. To mitigate this possibility, astrocytes were individually collected, but it is possible that astrocytic end feet may have been missed. As a secondary confirmation, we evaluated GFAP expression and identified increased expression in AD subjects (uncorrected p ¼ 1.63 Â 10 À3 , log2 fold ¼ 2.49), as expected because of upregulation of GFAP in reactive astrocytes in AD (Eng et al., 2000; Panter et al., 1985; Sofroniew and Vinters, 2010) , although we did not specifically collect GFAP-positive cells. Another limitation is that we do not know the mitochondrial content of the microdissected cells, whereby differential expression of mitochondrial genes may reflect differential mitochondrial loads. Differences in mitochondrial content in both astrocytes and neurons in the context of AD have yet to be investigated. Third, it is not known if increased expression of mitochondrial genes directly translates to activation of energy metabolism pathways. This study is also prefaced by significant region-specific transcriptional analyses in AD that have demonstrated discrete alterations in different areas of the brain. Key upregulated and downregulated genes have been identified in the amygdala and cingulate cortex of postmortem AD brains, correlating to processes including inflammation and energy metabolism, respectively (Loring et al., 2001) . Although analyses were performed on whole tissue, upregulation of inflammation genes and downregulation of energy metabolism genes parallel our findings here, in addition to our previous report of decreased expression of electron transport genes in PC neurons (Liang et al., 2008a (Liang et al., , 2008b . In a separate study, microarray analysis of LCMed CA1 hippocampal gray matter from formalin fixed paraffin embedded (FFPE) sections of AD brains suggests that increased expression of glial transcription factors genes, among others, may be concentrated in white, and not gray, matter (Blalock et al., 2011) . Although transcriptional analysis of FFPE samples may be associated with decreased specificity, this study provides evidence of divergent expression changes also at the level of gray and white matter. In neuron-specific transcriptomic studies in AD, key expression alterations were also identified across multiple brain regions, including the PC, hippocampal CA1, and middle temporal gyrus, in cortical neurons (Liang et al., 2008a (Liang et al., , 2008b (Liang et al., , 2010 .
Such findings emphasize the need to consider cell-specific responses, roles, and contributions to AD pathogenesis. The benefits of RNAseq support our ability to perform cell-specific analyses by widening the dynamic range for transcript detection and by supporting an unbiased evaluation of all transcripts in a sample. Furthermore, identification of differentially expressed mitochondrial and immune response genes, and the respective roles of these genes in Ab generation and clearance, lends valuable insight into previously uncharacterized cells in the PC. As we continue to improve our understanding of the discrete molecular events that occur in the PC in AD, we will strengthen our ability to identify potential targets for slowing and arresting disease progression at earlier stages of AD.
